Boothbay Fund Management’s Lifecore Biomedical LFCR Stock Holding History

Boothbay Fund Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$161K	Buy	+30,670	New	+$154K	﹤0.01%	1979
2025 Q4	–	Sell	-29,964	Closed	-$221K	–	2180
2025 Q3	$221K	Buy	+29,964	New	+$227K	﹤0.01%	1608
2025 Q1	–	Sell	-87,142	Closed	-$647K	–	1606
2024 Q4	$647K	Sell	87,142 -100,004	-53%	-$639K	0.02%	788
2024 Q3	$923K	Buy	187,146 +174,896	+1,428%	+$914K	0.02%	781
2024 Q2	$62.8K	Sell	12,250 -57,854	-83%	-$343K	﹤0.01%	1393
2024 Q1	$372K	Buy	70,104 +58,581	+508%	+$419K	0.01%	1126
2023 Q4	$71.3K	Buy	+11,523	New	+$80K	﹤0.01%	1482

Other funds holding LFCR

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Boothbay Fund Management's LFCR Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Lifecore Biomedical (LFCR) in Q2 2026: 30,670 shares worth $161K. The stake represents ﹤0.01% of the portfolio and ranks #1979 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in LFCR as recently as Q3 2025.

Boothbay Fund Management first reported a position in LFCR in Q4 2023 and has held it in 7 quarters since. The position peaked at $923K in Q3 2024. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

Boothbay Fund Management held 30,670 shares of Lifecore Biomedical worth $161K as of Q2 2026.
Lifecore Biomedical was a new Boothbay Fund Management position in Q2 2026.
Lifecore Biomedical made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1979 holding.
Boothbay Fund Management first reported a position in Lifecore Biomedical in Q4 2023 and has held it in 7 quarters since.
Boothbay Fund Management's Lifecore Biomedical position peaked at $923K in Q3 2024.
99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.